Compare Crispr Therapeutics AG (CRSP) vs SkyWest Inc (SKYW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs SkyWest Inc — how do they compare? Crispr Therapeutics AG trades at $54 (market cap $5.23B), while SkyWest Inc trades at $107.89 (market cap $4.19B). The key difference: Crispr Therapeutics AG is the larger of the two by market cap, and SkyWest Inc is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| CRSP | SKYW | |
|---|---|---|
Market Cap | $5.23B | $4.19B |
Sector | Health | Technology |
52-Week High | $76.78 | $123.72 |
52-Week Low | $44.34 | $78.40 |
Enterprise Value | $3.65B | $5.97B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $54.02, up 0.95% on the day, with strong technical momentum and bullish moving average signals. The company reported a Q2 2026 loss of $0.94 per share, beating estimates, while revenue growth is driven by CASGEVY sales expansion. Analyst sentiment remains positive with a $82.67 consensus price target representing 53% upside potential.
Despite promising pipeline developments and strong analyst support, CRSP faces significant fundamental challenges including negative profit margins, substantial cash burn, and high valuation multiples. The stock's near-term performance will depend on successful clinical trial outcomes and commercial execution of its gene-editing therapies.
SkyWest (SKYW) trades at $107.23, down 0.41% today, with a bullish technical signal from moving averages and neutral oscillators. The stock shows solid fundamentals with a P/E of 10.72 and net income margin of 9.78%, though Q2 2026 earnings missed estimates. Recent news highlights executive stock sales amid company buybacks, while analyst consensus remains positive with a $109.33 price target. Cash flow improved in 2026 to a net positive $33 million from a $105 million deficit in 2025.
The outlook for SKYW is cautiously optimistic, supported by undervalued metrics and bullish analyst ratings, but risks include earnings volatility and insider selling. Investment opportunity lies in its low valuation and operational cash flow growth, though investors should monitor fuel cost pressures and competitive dynamics in the airline industry.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About SkyWest Inc
SkyWest, Inc. is a major North American regional airline company, operating primarily through its subsidiary, SkyWest Airlines. The company provides regional airline service to various large airlines under contract, including United Airlines (as United Express), Delta Air Lines (as Delta Connection), American Airlines (as American Eagle), and Alaska Airlines (as Alaska SkyWest). SKYW's primary business is providing essential flight services, connecting smaller cities to major airline hubs across the United States.
Read more on SKYW →
